C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 314—Applications for Fda Approval to Market A New DrugSubpart D—Fda Action on Applications and Abbreviated Applications

21 C.F.R. § 314.127 (2026)

Refusal to approve an ANDA

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1996–2025 41citing cases
At a glance

Courts have cited this section in 41 opinions since 1996, 6 of them in the last five years. The most litigated part is subsection (a)(7) (2 cases).

(a) FDA will refuse to approve an ANDA for a new drug under section 505(j) of the Federal Food, Drug, and Cosmetic Act for any of the following reasons, unless the requirement has been waived under § 314.99:

(1) The methods used in, or the facilities and controls used for, the manufacture, processing, and packing of the drug product are inadequate to ensure and preserve its identity, strength, quality, and purity.

(2) Information submitted with the ANDA is insufficient to show that each of the proposed conditions of use has been previously approved for the listed drug referred to in the ANDA.

(3)(i) If the reference listed drug has only one active ingredient, information submitted with the ANDA is insufficient to show that the active ingredient is the same as that of the reference listed drug;

(ii) If the reference listed drug has more than one active ingredient, information submitted with the ANDA is insufficient to show that the active ingredients are the same as the active ingredients of the reference listed drug; or

(iii) If the reference listed drug has more than one active ingredient and if the ANDAis for a drug product that has an active ingredient different from the reference listed drug:

(A) Information submitted with the ANDA is insufficient to show:

(1) That the other active ingredients are the same as the active ingredients of the reference listed drug; or

(2) That the different active ingredient is an active ingredient of a listed drug or a drug that does not meet the requirements of section 201(p) of the Federal Food, Drug, and Cosmetic Act; or

(B) No petition to submit an ANDA for the drug product with the different active ingredient was approved under § 314.93.

(4)(i) If the ANDA is for a drug product whose route of administration, dosage form, or strength purports to be the same as that of the listed drug referred to in the ANDA, information submitted in the abbreviated new drug application is insufficient to show that the route of administration, dosage form, or strength is the same as that of the reference listed drug; or

(ii) If the ANDA is for a drug product whose route of administration, dosage form, or strength is different from that of the listed drug referred to in the application, no petition to submit an ANDA for the drug product with the different route of administration, dosage form, or strength was approved under § 314.93.

(5) If the ANDA was submitted under the approval of a petition under § 314.93, the ANDA did not contain the information required by FDA with respect to the active ingredient, route of administration, dosage form, or strength that is not the same as that of the reference listed drug.

(6)(i) Information submitted in the ANDA is insufficient to show that the drug product is bioequivalent to the listed drug referred to in the ANDA; or

(ii) If the ANDA was submitted under a petition approved under § 314.93, information submitted in the ANDA is insufficient to show that the active ingredients of the drug product are of the same pharmacological or therapeutic class as those of the reference listed drug and that the drug product can be expected to have the same therapeutic effect as the reference listed drug when administered to patients for each condition of use approved for the reference listed drug.

(7) Information submitted in the ANDA is insufficient to show that the labeling proposed for the drug is the same as the labeling approved for the listed drug referred to in the ANDA except for changes required because of differences approved in a petition under § 314.93 or because the drug product and the reference listed drug are produced or distributed by different manufacturers or because aspects of the listed drug's labeling are protected by patent, or by exclusivity, and such differences do not render the proposed drug product less safe or effective than the listed drug for all remaining, nonprotected conditions of use.

(8)(i) Information submitted in the ANDA or any other information available to FDA shows that:

(A) The inactive ingredients of the drug product are unsafe for use, as described in paragraph (a)(8)(ii) of this section, under the conditions prescribed, recommended, or suggested in the labeling proposed for the drug product; or

(B) The composition of the drug product is unsafe, as described in paragraph (a)(8)(ii) of this section, under the conditions prescribed, recommended, or suggested in the proposed labeling because of the type or quantity of inactive ingredients included or the manner in which the inactive ingredients are included.

(ii)(A) FDA will consider the inactive ingredients or composition of a drug product unsafe and refuse to approve an ANDA under paragraph (a)(8)(i) of this section if, on the basis of information available to the agency, there is a reasonable basis to conclude that one or more of the inactive ingredients of the proposed drug or its composition raises serious questions of safety or efficacy. From its experience with reviewing inactive ingredients, and from other information available to it, FDA may identify changes in inactive ingredients or composition that may adversely affect a drug product's safety or efficacy. The inactive ingredients or composition of a proposed drug product will be considered to raise serious questions of safety or efficacy if the product incorporates one or more of these changes. Examples of the changes that may raise serious questions of safety or efficacy include, but are not limited to, the following:

(1) A change in an inactive ingredient so that the product does not comply with an official compendium.

(2) A change in composition to include an inactive ingredient that has not been previously approved in a drug product for human use by the same route of administration.

(3) A change in the composition of a parenteral drug product to include an inactive ingredient that has not been previously approved in a parenteral drug product.

(4) A change in composition of a drug product for ophthalmic use to include an inactive ingredient that has not been previously approved in a drug for ophthalmic use.

(5) The use of a delivery or a modified release mechanism never before approved for the drug.

(6) A change in composition to include a significantly greater content of one or more inactive ingredients than previously used in the drug product.

(7) If the drug product is intended for topical administration, a change in the properties of the vehicle or base that might increase absorption of certain potentially toxic active ingredients thereby affecting the safety of the drug product, or a change in the lipophilic properties of a vehicle or base, e.g., a change from an oleaginous to a water soluble vehicle or base.

(B) FDA will consider an inactive ingredient in, or the composition of, a drug product intended for parenteral use to be unsafe and will refuse to approve the ANDA unless it contains the same inactive ingredients, other than preservatives, buffers, and antioxidants, in the same concentration as the listed drug, and, if it differs from the listed drug in a preservative, buffer, or antioxidant, the ANDA contains sufficient information to demonstrate that the difference does not affect the safety or efficacy of the drug product.

(C) FDA will consider an inactive ingredient in, or the composition of, a drug product intended for ophthalmic or otic use unsafe and will refuse to approve the ANDA unless it contains the same inactive ingredients, other than preservatives, buffers, substances to adjust tonicity, or thickening agents, in the same concentration as the listed drug, and if it differs from the listed drug in a preservative, buffer, substance to adjust tonicity, or thickening agent, the ANDA contains sufficient information to demonstrate that the difference does not affect the safety or efficacy of the drug product and the labeling does not claim any therapeutic advantage over or difference from the listed drug.

(9) Approval of the listed drug referred to in the ANDA has been withdrawn or suspended for grounds described in § 314.150(a) or FDA has published a notice of opportunity for hearing to withdraw approval of the reference listed drug under § 314.150(a).

(10) Approval of the listed drug referred to in the ANDA has been withdrawn under § 314.151 or FDA has proposed to withdraw approval of the reference listed drug under § 314.151(a).

(11) FDA has determined that the reference listed drug has been withdrawn from sale for safety or effectiveness reasons under § 314.161, or the reference listed drug has been voluntarily withdrawn from sale and the agency has not determined whether the withdrawal is for safety or effectiveness reasons, or approval of the reference listed drug has been suspended under § 314.153, or the agency has issued an initial decision proposing to suspend the reference listed drug under § 314.153(a)(1).

(12) The abbreviated new drug application does not meet any other requirement under section 505(j)(2)(A) of the Federal Food, Drug, and Cosmetic Act.

(13) The abbreviated new drug application contains an untrue statement of material fact.

(14) For an ANDA submitted pursuant to an approved petition under § 10.30 of this chapter and § 314.93, an NDA subsequently has been approved for the change described in the approved petition.

(15) For an ANDA for a nonprescription drug product with an additional condition for nonprescription use under § 314.56, if FDA has determined the application failed to meet the requirements in § 314.56 applicable to ANDAs.

(b) FDA may refuse to approve an ANDA for a new drug if the applicant or contract research organization that conducted a bioavailability or bioequivalence study described in § 320.63 of this chapter that is contained in the ANDA refuses to permit an inspection of facilities or records relevant to the study by a properly authorized officer or employee of the Department of Health and Human Services or refuses to submit reserve samples of the drug products used in the study when requested by FDA.

[57 FR 17991, Apr. 28, 1992; 57 FR 29353, July 1, 1992, as amended at 58 FR 25927, Apr. 28, 1993; 67 FR 77672, Dec. 19, 2002; 81 FR 69658, Oct. 6, 2016; 89 FR 105331, Dec. 26, 2024]
The 20 cases that cite 21 C.F.R. § 314.127 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENSerono Labs Inc v. Ferring Pharm. Inc., 158 F.3d 1313 (D.C. Cir. 1998).
cites § 314.127 3×cited by 292 cases
Where it cites § 314.127
“” 21 C.F.R. § 314.127 (a)(8)(ii)(B). Repronex is intended for parenteral use and, although there is no dispute that the lactose in Repro-nex and Pergonal is the same, it is conceded that the concentration of lactose in the two drugs is different.”
The case’s holding
Courts must defer to the agency's technical expertise when determining whether a generic drug is bioequivalent to a reference drug under the statutory sameness requirement.
Later courts cite it for
“these factors interrelate on a sliding scale and must be balanced against each other.” · 27 citing courts
2
GREENBayer Schering Pharma Ag v. Lupin, Ltd., 676 F.3d 1316 (Fed. Cir. 2012).
cites § 314.127 2×cited by 33 cases
Where it cites § 314.127
“See 21 C.F.R. § 314.127 (a)(7); see also Applications for FDA Approval to Market a New Drug, 68 Fed.”
The case’s holding
A generic applicant cannot be liable for infringing a method-of-use patent where the FDA-approved label, read as a whole, does not recommend the drug for the claimed use.
Later courts cite it for
“the fda-approved label for an approved drug indicates whether the fda has approved a particular method of use for that drug.” · 2 citing courts
cites § 314.127 2×cited by 33 cases
Where it cites § 314.127
“§ 355 (j)(4)(G) and 21 C.F.R. § 314.127 (a)(7). (See DP Compl.”
The case’s holding
Product-hopping schemes involving new dosage forms, withdrawal of old products, and fraudulent marketing can plausibly state a claim for monopolization under Section 2 of the Sherman Act.
Later courts cite it for
“antitrust standing is not unlimited,” · 2 citing courts
4
GREENBartlett v. Mut. Pharm. Co., 659 F. Supp. 2d 279 (D.N.H. 2009).
cites § 314.127 2×cited by 21 cases
Where it cites § 314.127
“at 17992 (later codified at 21 C.F.R. § 314.127 (a)(7) (1993)), and that the FDA “may” begin proceedings to withdraw its approval of an ANDA if it found “[t]hat the labeling for the drug product that is the subject of the [ANDA] is no longer consistent with that for the listed…”
The case’s holding
Federal drug-labeling law does not impliedly preempt state-law failure-to-warn claims against a generic drug manufacturer, because federal rules allow post-approval labeling changes that could have strengthened the warnings.
Later courts cite it for
“the fda's remarks in proposing and promulgating these regulations” · 2 citing courts
cites § 314.127 1×cited by 73 cases
Where it cites § 314.127
“§ 355 (j)(2)(A)(v); 21 C.F.R. § 314.127 (a)(7). And if the generic drug is approved for use as a prescription drug, the label of the generic drug must “bear, at a minimum, the symbol ‘Rx only.”
The case’s holding
The doctrine of literal falsity applies only to patently false statements that mean what they say to any linguistically competent person, dispensing with the need to prove consumer deception.
Later courts cite it for
“meaning of the alleged literal falsehood must be considered in context and with reference to the audience to which the statement is addressed.” · 8 citing courts
6
GREENAmneal Pharm. LLC v. Food & Drug Admin., 285 F. Supp. 3d 328 (D.C. Cir. 2018).
cites § 314.127 3×cited by 4 cases
Where it cites § 314.127
“8:7), in which the agency generally requests additional data or information to determine whether the ANDA meets the requirements for approval, see 21 C.F.R. § 314.127 . This process can take years to complete.”
Later courts cite it for
“obtaining fda approval for an anda remains a prolonged” · 2 citing courts
7
GREENHill Dermaceuticals, Inc. v. U.S. Food & Drug Admin., 524 F. Supp. 2d 5 (D.D.C. 2007).
cites § 314.127 3×cited by 8 cases
Where it cites § 314.127
“§ 355 (j)(2)(A), (j)(4); 21 C.F.R. §§ 314.127 (a), 314.94(a). Most relevant to the current case is the requirement that an ANDA include information demonstrating that the generic drug is the "bioequi-valent” of the referenced innovator drug.”
Later courts cite it for
“the public interest weighs strongly in favor of preventing unsafe drugs from entering the market.” · 2 citing courts
8
REDDemahy v. Actavis, Inc., 593 F.3d 428 (5th Cir. 2010).
cites § 314.127 1×cited by 37 cases
Reversed by the U.S. Supreme Court in this case: PLIVA, Inc. v. Mensing (2011).
Where it cites § 314.127
“94 (a)(8)(iv) (requiring that, as part of its ANDA application, a generic manufacturer give a side-by-side comparison of its proposed labeling with the approved labeling for the listed drug, with all differences annotated and explained); 21 C.F.R. § 314.127 (a)(7) (noting that…”
The case’s holding
Federal regulatory requirements for generic drugs do not preempt state law failure-to-warn claims because manufacturers can comply with both sets of laws through available regulatory processes.
Later courts cite it for
“generic manufacturers cannot send 'dear doctor' letters without prior fda approval” · 2 citing courts
9
GREENBristol-Myers Squibb Co. v. Donna E. Shalala, 91 F.3d 1493 (D.C. Cir. 1996).
cites § 314.127 1×cited by 50 cases
Where it cites § 314.127
“See also 21 C.F.R. § 314.127 (a)(7) (grounds upon which FDA will deny ANDA).”
The case’s holding
A competitor has standing to challenge agency action when a statutory provision reflects a legislative purpose to protect a competitive interest.
Later courts cite it for
“wjhere ... a statutory provision reflects a legislative purpose to protect a competitive interest, the protected competitor has standing to require compliance with that provision.” · 5 citing courts
10
GREENFMC Corp. v. Control Solutions, Inc., 369 F. Supp. 2d 539 (E.D. Pa. 2005).
cites § 314.127 1×cited by 18 cases
Where it cites § 314.127
“§ 355 (j)(2)(A)(v); see also 21 C.F.R. § 314.127 (a)(7) (“FDA will refuse to approve an abbreviated application for a new drug under section 505(j) of the act [if] .”
Later courts cite it for
“an unreasonable delay in seeking an injunction negates the presumption of irreparable harm.” · 2 citing courts
11
YELLOWMensing v. Wyeth, Inc., 562 F. Supp. 2d 1056 (D. Minn. 2008).
cites § 314.127 1×cited by 17 cases
Flagged on editorial review. Overruled by Mensing v. Wyeth, Inc.
Where it cites § 314.127
“” 21 C.F.R. § 314.127 (a)(7). Moreover, the FDA may withdraw approval of a generic drug if the labeling for the generic product varies from that of the listed drug.”
Later courts cite it for
“is no longer consistent with that for the listed drug,” · 2 citing courts
12
GREENSpectrum Pharm., Inc v. Sylvia Burwell, 824 F.3d 1062 (D.C. Cir. 2016).
cites § 314.127 1×cited by 7 cases
Where it cites § 314.127
“§ 355a); 21 C.F.R. § 314.127 (a)(7). Accordingly, whether large vials are necessary for the Methotrexate Indications is beside the point: FDA’s statement to that effect says nothing about whether large vials are safe and effective for the Methotrexate Indications, which is the…”
Later courts cite it for
“designed to treat a rare disease or condition that historically received little attention from pharmaceutical companies.” · 2 citing courts
13
GREENGaeta v. Perrigo Pharm. Co., 562 F. Supp. 2d 1091 (N.D. Cal. 2008).
cites § 314.127 1×cited by 14 cases
Summary
No passage or summary on file for this case yet.
14
GREENAstellas Pharma US, Inc. v. Food & Drug Admin., 642 F. Supp. 2d 10 (D.D.C. 2009).
cites § 314.127 1×cited by 12 cases
Where it cites § 314.127
“§ 3550(2)(A)(iv); 21 C.F.R. § 314.127 (a)(6)® (stating that the FDA will refuse approval of an ANDA if the information submitted “is insufficient to show that the drug product is bioequivalent to the listed drug referred to in the abbreviated new drug application”).”
Later courts cite it for
“rather than requiring the anda applicant to make an independent showing that the proposed generic is itself safe and effective, the amended statute requires a showing that the proposed generic operates in the same manner as the pioneer drug on which it is based.” · 2 citing courts
15
REDPfizer Inc. v. Shalala, 1 F. Supp. 2d 38 (D.D.C. 1998).
cites § 314.127 4×subsections: (a)(8)(ii)(A)cited by 3 cases
Reversed in part by Pfizer Inc v. Shalala, Donna E. (1999): the Court of Appeals for the D.C. Circuit's own opinion in this case ("*981 The judgment of the district court is therefore Affirmed in part and reversed in part.").
Where it cites § 314.127
“” Guidance, Oral Extended (Controlled) Dissolution Testing (1993) at 2 (attachment F to Gov’t Mem. in Support of Mot. to Dismiss).”
16
GREENIsta Pharm., Inc. v. Food & Drug Admin., 898 F. Supp. 2d 227 (D.D.C. 2012).
cites § 314.127 2×cited by 4 cases
Where it cites § 314.127
“Xibrom was not removed for safety reasons ISTA next claims that the FDA violated 21 C.F.R. § 314.127 (a)(ll) and 21 U.S.C.”
Later courts cite it for
“the fda's administrative decisions are subject to review under the administrative procedure act ('apa'), 5 u.s.c. 706 , which requires the reviewing court to set aside an agency action that is 'arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law.” · 2 citing courts
17
GREENAstrazeneca Pharm. Lp v. Food & Drug Admin., 850 F. Supp. 2d 230 (D.D.C. 2012).
cites § 314.127 1×cited by 10 cases
Where it cites § 314.127
“” 21 C.F.R. § 314.127 (a)(1). In other words, the FDA may deny final approval to one or all of the potential generic competitors seeking to market a generic version of Seroquel or Seroquel XR “for some entirely different reason” than the one pressed by AstraZeneca in this case.”
18
GREENTeva Pharm. United States, Inc. v. Azar, 369 F. Supp. 3d 183 (D.C. Cir. 2019).
cites § 314.127 1×cited by 4 cases
Where it cites § 314.127
“See 21 C.F.R. § 314.127 (setting forth numerous reasons for which the FDA will refuse to approve an ANDA).”
19
GREENSerono Labs., Inc. v. Shalala, 974 F. Supp. 29 (D.D.C. 1997).
cites § 314.127 3×subsections: (a)(8)(ii)(B)cited by 3 cases
Where it cites § 314.127
“” 21 C.F.R. § 314.127 (a)(8)(ii)(B). The agency’s rationale for requiring equivalence with regard to inactive ingredients is based on its conclusion “that changing the inactive ingredients in a drug can adversely affect the drug’s safety or effectiveness.”
20
GREENFulgenzi v. Wyeth, Inc., 686 F. Supp. 2d 715 (N.D. Ohio 2010).
cites § 314.127 1×cited by 7 cases
Where it cites § 314.127
“]” 21 C.F.R. § 314.127 (a)(7). Post-approval, a manufacturer has the ability to submit additional information to the FDA to, among other things, change the drug’s label “[t]o add or strengthen a contraindication, warning, precaution, or adverse reaction.”
Later courts cite it for
“multiple state law tort claims, including several claims sounding in fraud” · 3 citing courts

Show all 41 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199620102025

One bar per year. Tallest: 6 cases in 2009. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D.D.C.16D.C. Cir.72d Cir.27th Cir.2D.N.H.2N.D. Ohio2E.D. Pa.23rd Cir.1

The 8 courts with the most citing cases, of 15 courts in all.

By subsection
(a)(7)2 cases
Novartis Pharm. Corp. v. Becerra, No. 2024-2234 (D.D.C. Oct. 15, 2024).
(a)(8)(ii)(A)1 case
Pfizer Inc. v. Shalala, 1 F. Supp. 2d 38 (D.D.C. 1998).“” Guidance, Oral Extended (Controlled) Dissolution Testing (1993) at 2 (attachment F to Gov’t Mem. in Support of Mot. to Dismiss).”
(a)(8)(ii)(B)1 case
Serono Labs., Inc. v. Shalala, 974 F. Supp. 29 (D.D.C. 1997).“” 21 C.F.R. § 314.127 (a)(8)(ii)(B). The agency’s rationale for requiring equivalence with regard to inactive ingredients is based on its conclusion “that changing the inactive ingredients in a drug can adversely affect the drug’s safety or effectiveness.”

Show all 41 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com